Charalampos G. Filippatos

Athens, ESYE31, Greece

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 38 publications

Independent prognostic value of semaphorin-4D, interleukin-1β and complement activation in newly diagnosed multiple myeloma patients.

Independent prognostic value of semaphorin-4D, interleukin-1β and complement activation in newly diagnosed multiple myeloma patients.

Journal: Haematologica

Published: May 13, 2026

Efficacy and Safety of PD-1 Inhibitor-Based Regimens in Patients with Melanoma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Efficacy and Safety of PD-1 Inhibitor-Based Regimens in Patients with Melanoma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Journal: Journal of clinical medicine

Published: May 10, 2026

Improved Survival With Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Patients With Heart Failure With Preserved Ejection Fraction and Metabolic Dysfunction-Associated Steatotic Liver Disease.

Improved Survival With Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Patients With Heart Failure With Preserved Ejection Fraction and Metabolic Dysfunction-Associated Steatotic Liver Disease.

Journal: American journal of therapeutics

Published: May 06, 2026

Management and long-term haematological and neurological outcomes of Immunoglobulin M and Waldenström's macroglobulinaemia-related neuropathy: A single-centre experience.

Management and long-term haematological and neurological outcomes of Immunoglobulin M and Waldenström's macroglobulinaemia-related neuropathy: A single-centre experience.

Journal: British journal of haematology

Published: April 27, 2026

Sotatercept as an Add-On to Background Therapy in Idiopathic Pulmonary Arterial Hypertension: Insights from a Real-World Cohort.

Sotatercept as an Add-On to Background Therapy in Idiopathic Pulmonary Arterial Hypertension: Insights from a Real-World Cohort.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: April 24, 2026

Response to Methodological Concerns Regarding Eligibility Criteria and Study Selection in a Systematic Review and Meta-Analysis of CAR T-Cell Therapy for Hematologic Malignancies.

Response to Methodological Concerns Regarding Eligibility Criteria and Study Selection in a Systematic Review and Meta-Analysis of CAR T-Cell Therapy for Hematologic Malignancies.

Journal: American journal of hematology

Published: April 16, 2026

GLP-1 Receptor Agonist Therapy and Cardiorenal Outcomes in Type 1 Diabetes: A Propensity-Matched Real-World Analysis.

GLP-1 Receptor Agonist Therapy and Cardiorenal Outcomes in Type 1 Diabetes: A Propensity-Matched Real-World Analysis.

Journal: Diabetes, obesity & metabolism

Published: March 23, 2026

The Role of Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma With Renal Impairment: A Systematic Review.

The Role of Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma With Renal Impairment: A Systematic Review.

Journal: American journal of hematology

Published: March 19, 2026

Safety profile of chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma: A systematic review and meta-analysis of proportions from clinical trials.

Safety profile of chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma: A systematic review and meta-analysis of proportions from clinical trials.

Journal: British journal of haematology

Published: March 19, 2026

Real-world cardiovascular safety profile of bexarotene for the treatment of mycosis fungoides.

Real-world cardiovascular safety profile of bexarotene for the treatment of mycosis fungoides.

Journal: Clinical and experimental medicine

Published: March 18, 2026

A Prospective Study of Familial Predisposition in Plasma Cell Dyscrasias.

A Prospective Study of Familial Predisposition in Plasma Cell Dyscrasias.

Journal: Blood advances

Published: March 11, 2026

Validation of the new IMS/IMWG consensus genomic staging (CGS) of high-risk multiple myeloma (HRMM) in a contemporary cohort of 1209 patients.

Validation of the new IMS/IMWG consensus genomic staging (CGS) of high-risk multiple myeloma (HRMM) in a contemporary cohort of 1209 patients.

Journal: HemaSphere

Published: March 09, 2026

Showing 1-12 of 38

Last Updated: 09/26/2026